Fairmount Funds Management LLC - Nov 24, 2023 Form 4 Insider Report for Spyre Therapeutics, Inc. (AGLE)

Role: Director, 10%+ Owner
Signature: /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Stock symbol: AGLE
Transactions as of: Nov 24, 2023
Transactions value $: $0
Form type: 4
Date filed: 11/28/2023, 04:05 PM
Previous filing: Nov 1, 2023
Next filing: Dec 11, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AGLE	Common Stock	Conversion of derivative security	$0	+3.44M	$0.00	3.44M	Nov 24, 2023	By Fairmount Healthcare Co-Invest L.P.	F1, F2
holding	AGLE	Common Stock					11K	Nov 24, 2023	By Fairmount Healthcare Fund L.P.	F2
holding	AGLE	Common Stock					367K	Nov 24, 2023	By Fairmount Healthcare Fund II L.P.	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Ownership	Footnotes
transaction	AGLE	Series A Preferred Stock	Conversion of derivative security	$0	-85.9K	-100%	$0.00^*	0	Nov 24, 2023	Common Stock	3.44M	By Fairmount Healthcare Co-Invest L.P.	F1, F2
holding	AGLE	Series A Preferred Stock						12.7K	Nov 24, 2023	Common Stock	507K	By Fairmount Healthcare Fund L.P.	F1, F2
holding	AGLE	Series A Preferred Stock						424K	Nov 24, 2023	Common Stock	17M	By Fairmount Healthcare Fund II L.P.	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations.
F2	Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P., Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Content

Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations.

Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P., Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Remarks:

The Reporting Persons may each be deemed a director by deputization of Issuer by virtue of the fact that each of Peter Harwin and Tomas Kiselak serve on the board of directors of Issuer and are also each a Managing Member of Fairmount Funds Management LLC.